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Behavioral training rescues motor deficits
in Cyfip1 haploinsufficiency mouse model
of autism spectrum disorders
Sven O. Bachmann 1, Monika Sledziowska1, Ellen Cross1, Shireene Kalbassi1, Sophie Waldron1, Fangli Chen2,
Adam Ranson 2,3 and Stéphane J. Baudouin 1
Abstract
Deletions in the 15q11.2 region of the human genome are associated with neurobehavioral deficits, and motor
development delay, as well as in some cases, symptoms of autism or schizophrenia. The cytoplasmic FMRP-interacting
protein 1 (CYFIP1) is one of the four genes contained within this locus and has been associated with other genetic
forms of autism spectrum disorders (ASD). In mice, Cyfip1 haploinsufficiency leads to alteration of dendritic spine
morphology and defects in synaptic plasticity, two pathophysiological hallmarks of mouse models of ASD. At the
behavioral level, however, Cyfip1 haploinsufficiency leads to minor phenotypes, not directly relevant for 15q11.2
deletion syndrome or ASD. A fundamental question is whether neuronal phenotypes caused by the mutation of Cyfip1
are relevant for the human condition. Here, we describe a synaptic cluster of ASD-associated proteins centered on
CYFIP1 and the adhesion protein Neuroligin-3. Cyfip1 haploinsufficiency in mice led to decreased dendritic spine
density and stability associated with social behavior and motor learning phenotypes. Behavioral training early in
development resulted in alleviating the motor learning deficits caused by Cyfip1 haploinsufficiency. Altogether, these
data provide new insight into the neuronal and behavioral phenotypes caused by Cyfip1 mutation and proof-of-
concept for the development of a behavioral therapy to treat phenotypes associated with 15q11.2 syndromes and
ASD.
Introduction
Autism spectrum disorders (ASD) are defined by per-
sistent deficits in social communication and social inter-
action accompanied by restricted, repetitive patterns of
behavior, interests, or activities. In addition to these core
symptoms, more than 70% of individuals with ASD have
co-occurring medical, developmental, or psychiatric
conditions1. An extensive variety of impairments affecting
gross and fine motor functions affect more than 79% of
individuals with ASD1. Despite the frequency of motor
anomalies, studies on the underlying pathophysiology of
motor deficits and their treatment remain limited.
Deletions in the 15q11.2 region of the human genome
are associated with neurobehavioral deficits, and motor
development delay and, in about 30% of individuals,
symptoms of autism2. The 15q11.2 locus contains four
genes, tubulin gamma complex-associated protein 3
(TUBGCP3), cytoplasmic FMR1 interacting protein 1
(CYFIP1), and non-imprinted in Prader-Willi/Angelman
syndrome 1 and 2 (NIPA1/2)), and is also associated with
larger 15q11–q13 type I deletions causing Prader-Willi or
Angelman Syndromes3. Microdeletions of 15q11.2 cor-
related with decreased TUBGCP3, CYFIP1, and NIPA1/2
mRNA levels in lymphoblastoid cells derived from
patients with Prader-Willi syndrome4. The four genes in
the 15q11.2 locus were shown to impact on the behavioral
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symptoms of patients with 15q11.2 deletion or Prader-
Will syndrome. In addition, decreased CYFIP1 mRNA
levels were also found in leukocytes obtained from ASD
diagnosed patients with Fragile X and in patients diag-
nosed with autism and carrying a deletion of SH3 and
multiple ankyrin repeat domains 2 (SHANK2) gene.
Amongst the genes within region 15q11.2, CYFIP1 is of
particular interest due to its role in the control of actin
dynamics5,6 and protein translation7. This regulation
occurs through its interaction with the Wiskott–Aldrich
syndrome protein family verprolin-homologous protein
(WAVE) regulatory complex (WRC)5,6, and fragile X
mental retardation protein (FMRP)7, respectively. Hip-
pocampal neurons with Cyfip1 haploinsufficiency (Cy®-
p1HET) show defects in dendritic spine morphogenesis
and increased metabotropic glutamate receptor-induced
long-term depression8,9, two phenotypes consistently
found in mouse models of ASD and in particular Fragile X
syndrome10–12. Importantly, analyses of post-mortem
tissue of individuals with idiopathic and syndromic
forms of ASD also showed alteration of dendritic spine
morphology11. These results show that the effects of
deletion of Cyfip1 resemble the cellular phenotypes found
in other models of ASD. However, mice heterozygous for
Cyfip1 (Cyfip1HET) show mild behavioral phenotypes8,13.
It is, therefore, possible that CYFIP1 function at synapses
is not relevant for ASD or that the behavioral phenotyping
of Cyfip1HET mice was not conducted extensively enough.
Within the WRC, CYFIP1, and Abi interactor proteins
1–3 (ABI1–3) form an interaction surface that enables the
interaction with proteins containing a WRC interacting
receptor sequence (WIRS). The coding sequence of
synaptic adhesion proteins Neuroligin-3 contains a WIRS
and is therefore predicted to interact with CYFIP1 and
Fig. 1 Binding between Neuroligin-3 and Cyfip1 in Pvalb-expressing neurons. a Western blot analysis showing that Neuroligin-1, 2, and 3 (NL1,
2, and 3) and Cyfip1 are detected in proteins co-immunoprecipitated with Neuroligin-3 in wild-type striatum (St), cerebellum (Cb), and cortex (Cx).
Note that FMRP is not detected in co-immunoprecipitated proteins. b Western blot analysis showing that Neuroligin-2 (NL2), Cyfip1, and FMRP are
detected in proteins co-immunoprecipitated with Neuroligin-3 in striatum (St), cerebellum (Cb), and cortex (Cx) of Nlgn3KOPvalbCre mice. Note that
Neuroligin-1 was not detected in co-immunoprecipitated proteins. c Two-step cluster analysis of proteins co-immunoprecipitated with Neuroligin-3
in wild-type mice VNO, Nlgn3KOPvalbCre striatum (St), and cerebellum (Cb) but not in Nlgn3KO mice VNO. d Bar graphs show the number of proteins
per cluster and per anatomical region. e Details of the anatomical region (VNO (V), striatum (S), or cerebellum (C)) and cluster in which proteins coded
by genes associated with ASD and co-immunoprecipitated with Neuroligin-3 are detected
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ABI 1–3. The genes coding for these proteins have been
associated with ASD in humans14–19. A putative interac-
tion between Neuroligin-3, CYFIP1, and FMRP would
point towards a possible common pathway linking ASD-
associated proteins at synapses. Mice lacking Neuroligin-3
or FMRP show defects of social behavior and motor
learning deficits correlated20–25 with alterations of den-
dritic spine stability26,27. Based on this predicted interac-
tion, we hypothesized that Cyfip1Het mice also show
defects in social and motor behaviors. This study exam-
ines these possibilities by immunoprecipitation paired
with mass-spectrometry, analysis of dendritic spine plas-
ticity in vivo and behavioral analysis. Based on the results
obtained, we investigated the possibility rescuing Cyfi-
p1HET mice motor learning phenotype using a behavioral
approach.
Results
The interaction between Neuroligin-3 and CYFIP1 was
investigated using immunoprecipitation of Neuroligin-3
in striatum, cerebellum, and cortex, followed by western
blot analysis. Neuroligin-3 co-immunoprecipitates
Neuroligin-1 and 2, two previously characterized inter-
actors of Neuroligin-328, and CYFIP1 (Fig. 1a). CYFIP1
was detected in the three different brain regions indicat-
ing that the interaction between Neuroligin-3 and CYFIP1
is not restricted to a particular brain region. Note that
FMRP was not detected in these samples. Further inves-
tigations revealed that CYFIP1 was also present in
Neuroligin-3 immunoprecipitates from synaptosomes but
again FMRP was not (Supplementary Figure 1a).
Neuroligin-3 is expressed in neurons but also in astro-
cytes29. To determine if the interaction between
Neuroligin-3 and CYFIP1 occurs in neurons, immuno-
precipitations were performed on brain samples origi-
nating from mice expressing Neuroligin-3 only in Pvalb-
expressing neurons (Nlgn3KOPvalbCre), as we previously
showed that re-expressing Neuroligin-3 in these cells was
sufficient to restore the ASD-related deficits in Nlgn3
knockout mice21. Neuroligin-3 neuronal co-
immunoprecipitated proteins from the three brain
regions contained Neuroligin-2 and CYFIP1, indicating
that indeed interaction between these proteins occurs in
neurons and is not grossly influenced by the regional
localization of Pvalb-expressing neurons (Fig. 1b and
supplementary Fig. 1b). Interestingly, proteins from
Nlgn3KOPvalbCre, co-immunoprecipitated with Neuroli-
gin-3, did not contain Neuroligin-1 but did contain
FMRP, suggesting that the identity of the proteins inter-
acting with the Neuroligin-3/CYFIP1 complex vary
depending on the cell type.
Studies suggest that CYFIP1's interaction with FMRP
and WRC is mutually exclusive7. To determine if the
Neuroligin-3/CYFIP1 complex interacts exclusively with
FMRP or also contains components of the WRC we
performed an unbiased screen of Neuroligin-3 co-
immunoprecipitated proteins using mass-spectrometry.
The synapse-specific interactome of Neuroligin-3 was
investigated, in vivo, in Nlgn3KOPvalbCre mice tissue (N=
3, supplementary Table 1), and in tissue expressing
Neuroligin-3 but lacking synapses (N= 3, supplementary
Table 2), as a control. The so-called olfactory ensheathing
cells (OEC) populating the vomeronasal organ (VNO)
fulfill these criteria as they are known to express
Neuroligin-330, but are entirely devoid of synapses. Note
that, biochemical analysis and in situ hybridization
demonstrated that Neuroligin-3 is expressed in non-
neuronal cells in the VNO, confirming its expression in
OEC (supplementary Fig. 2a–d). To determine proteins
specifically associated with Neuroligin-3 in Pvalb-
expressing interneurons, we performed co-
immunoprecipitation of Neuroligin-3 coupled with
mass-spectrometry analysis and included co-
immunoprecipitation of the VNOs of wild-type (N= 3,
supplementary Table 2) and Nlgn3KO mice (N= 2) to our
analysis to control for non-neuronal co-immunoprecipi-
tated proteins and unspecific binding of the Neuroligin-3
antibody, respectively (Supplementary Tables 1 and 2).
We used hierarchical cluster analysis of co-
immunoprecipitated proteins in wild-type mice VNO or
Nlgn3KOPvalbCre mice striatum or cerebellum but not in
Nlgn3KO mice VNO to determine the optimal number of
clusters in our dataset, which was found to be three. On
this basis, follow-up two-step cluster analysis showed that
clusters 1, 2, and 3 contained 42.6%, 42.1%, and 15.3% of
co-immunoprecipitated proteins, respectively (Fig. 1c).
Analysis of the number of co-immunoprecipitated pro-
teins contained in each cluster revealed that cluster 1
proteins almost uniquely originated from the striata and
cluster 2 proteins originated from the three anatomical
regions (Fig. 1d). Interestingly, cluster 3 was mostly
composed of proteins co-immunoprecipitated from
striata and/or cerebella but not VNOs, suggesting the
existence of proteins interacting with Neuroligin-3 spe-
cifically in neurons. Consistent with Neuroligin-3 synaptic
localization in neurons, excitatory (PSD93 and 95 and
synapse-associated protein 97 and 102), and inhibitory
synaptic proteins (Neuroligin-2 and Neuroligin-4 and
Gephyrin) were co-immunoprecipitated only in Pvalb-
expressing neurons independently of the brain region
(Supplementary Table 3). As FMRP, WAS protein family
member 1 (WASF1) and ABI1 were detected in proteins
immunoprecipitated by Neuroligin-3. FMRP was detected
in Nlgn3KOPvalbCre mice cerebella and striata, whereas
WASF1 and ABI1 were only detected in striata (Supple-
mentary Table 3). These results suggest that binding
between Neuroligin-3 and CYFIP1 and WRC is influenced
by the localization of the Pvalb-expressing cells
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(Supplementary Table 3). Interestingly, the protein pro-
ducts of genes reliably associated with syndromic and
non-syndromic ASD (with an SFARI gene score of 1, 2, or
3) were also co-immunoprecipitated only in Pvalb-
expressing interneurons, independently of the brain
region (Fig. 1e). Altogether, these results show that
Neuroligin-3 and CYFIP1 interact in neurons in vivo and
that the identity of the proteins they interact with is
influenced by the regional localization of the neurons.
Moreover, they suggest that CYFIP1 may interact with
other ASD-associated proteins at excitatory and inhibi-
tory synapses, either directly or indirectly via its binding
to Neuroligin-3 (Supplementary Fig. 1b).
Mice lacking Fmr1 or Nlgn3 show behavioral pheno-
types associated with the core symptoms of ASD,
including defects in social behavior, but also with some of
its comorbidities (e.g. hyperactivity, alteration of motor
learning)21,25,31–34. We hypothesized that since CYFIP1
interacts with both Neuroligin-3 and FMRP, the beha-
vioral phenotype should be similar across the three
models. A complete absence of Cyfip1 is embryonic
lethal7, therefore we used a Cyfip1HET mouse model.
Cyfip1HET mice showed an absence of interest for social
cues compared to their Cyfip1WT littermates (Fig. 2a)
without deficits in social dominance (courtship vocaliza-
tion test, Fig. 2b) or repetitive behaviors (marble burying
test, Fig. 2c). In addition, Cyfip1HET mice showed motor
learning deficits, as indicated by the absence of an
improved performance in the rotarod test, compared to
their Cyfip1WT littermates (Fig. 2d), but no change in
basal motor activity (Fig. 2e, f). The biochemical char-
acterization of Cyfip1HET mice showed a significant
decrease of CYFIP1 protein expression levels in motor
and frontal cortex and in the hippocampus but no change
in other brain regions or in the periphery (Supplementary
Fig. 3). Cyfip1HET mice phenotype is consistent with the
region-specific decrease of CYFIP1 protein expression
since frontal and motor areas of the cortex are involved in
the control of social and motor functions. In addition, the
behavioral phenotype of Cyfip1HET mice is also consistent
Fig. 2 Cyfip1 haploinsufficiency leads to motor learning defects. a Cyfip1HET mice spent a similar amount of time sniffing control, non-social, odor
(C) and social odor (S), whereas their Cyfip1WT littermate spent more time sniffing the social odor (S) than the control one (C). b Cyfip1HET mice and
their Cyfip1WT littermates spent a similar amount of time calling when exposed to females in estrus. c Cyfip1HET mice and their Cyfip1WT littermates
buried a similar number of marbles. d The time Cyfip1WT mice spent on an accelerating rotarod significantly increased over seven trials, whereas that
of Cyfip1HET did not. e Cyfip1WT and Cyfip1HET mice spent similar amounts of time on an accelerating rotarod on the first trial. f Cyfip1WT and Cyfip1HET
mice’s velocity in the open field was similar. In (a) connected dots represent the same animal tested for the control (C) and the social (S) odors. All
values in (b)–(d) are represented as mean ± SEM. In (a) and (d), statistical significance was tested by repeated measures ANOVA followed by
Bonferroni Post-hoc test. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; and ****P ≤ 0.0001. In (b), (c), (e), and (f), statistical significance was tested by two-tailed
Student’s t-test or one-tailed Mann–Whitney test
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with the association between CYFIP1 and 15q11.2 dele-
tion syndrome and ASD in humans, therefore validating
the use of the mouse model for ASD studies.
Cyfip1HET hippocampal neurons show deficits in den-
dritic spine maturation in vitro and ex vivo9, a converging
cellular phenotype between syndromic and non-
syndromic genetic mouse models of ASD10,11. Decreased
dendritic spine maturation can be explained by defects in
dendritic spine formation and/or dendritic spine
instability. To investigate these two possibilities, we
crossed Cyfip1HET mice with mice expressing green
fluorescent proteins in a subset of neurons (refer to
Material and methods) and imaged dendritic spines of
cortical neurons ex vivo and in vivo in adult male mice.
Immunohistology experiments demonstrated that
Cyfip1HET mice showed decreased dendritic spine density
in neurons from motor cortex but not from the V1 area of
the visual cortex, compared to their Cyfip1WT littermates
(Fig. 3a). Two-photon imaging to track dendritic spines in
the motor cortex in vivo revealed an increased formation
and elimination of dendritic spines over time, in Cyfi-
p1HET mice, compared to Cyfip1WT littermates (Fig. 3b,
c). Since increased rotarod performance correlates with
increased formation of dendritic spines35, we hypothe-
sized that, in addition to increased dendritic spine
instability, Cyfip1HET mice show defects in dendritic spine
formation. As previously demonstrated35, motor training
increased the formation of dendritic spines by about
three-fold in Cyfip1WT mice without affecting the number
of eliminated spines (Fig. 3d). Despite their lack of
Fig. 3 Cyfip1 haploinsufficiency leads to decreased stability of dendritic spines without affecting their formation. a Dendrites of GFP-
expressing neurons from the motor cortex (M1), visual cortex (V1), and hippocampus (CA1 and CA3) of Cyfip1WT and Cyfip1HET mice. Scale bars
represent 10 μm. Quantification of spine density of Cyfip1WT and Cyfip1HET dendrites. b Two images of the same dendrite of a Cyfip1WT mice motor
neuron taken at an interval of 2 days showing the newly formed dendritic spines (arrows). Scale bars represent 2 μm. c Quantification of formed and
eliminated dendritic spines in motor cortices of Cyfip1WT and Cyfip1HET mice. d Quantification of formed dendritic spines in motor cortices of Cyfip1WT
and Cyfip1HET mice before (B) and after rotarod training (R). All values are represented as mean ± SEM. In (b) and (d), statistical significance was tested
by ANOVA followed by Bonferroni post-hoc test. **P ≤ 0.01
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increased performance on the rotarod, Cyfip1HET mice
showed an increased number of newly formed dendritic
spines upon motor training similar to that of their
Cyfip1WT littermates (Fig. 3d). Note that rotarod training
had no effect on dendritic spine elimination in both
genotypes. These results show that while Cyfip1HET does
not impact on the ability to form new spines it leads to an
increased dendritic spines instability.
Given that Cyfip1HET mice show a similar ability to form
new spines upon training as Cyfip1WT mice, we hypothe-
sized that training Cyfip1HET mice during development,
before the appearance of the behavioral phenotype, would
be sufficient to rescue their motor learning deficits. The
earliest time point in the development animals complied
with the motor learning protocol was postnatal day 40
(P40), when Cyfip1WT mice show reliable decreased latency
to fall from an accelerating rod over successive trials (Fig.
4a). At P40, Cyfip1HET mice showed a decreased latency to
fall from the accelerating rod over successive trials (Fig. 4b).
These results indicate that Cyifp1HET mice motor learning
deficits develop after P40. To test our hypothesis we trained
Cyfip1WT and Cyfip1HET mice at postnatal days 40, 50, and
51 using the same rotarod protocol (in the following
referred to as ‘trained’ mice) and tested for their motor
behavior at P60. Trained Cyfip1WT mice showed an
increased latency to fall from an accelerating rod at trials 1
and 2 and no difference at the subsequent trials compared
to untrained Cyfip1WT mice, indicating that, as previously
demonstrated35, motor training increased the basal motor
performance of wild-type mice (Fig. 4c). Trained Cyfip1HET
mice showed a similar latency to fall from an accelerating
rod from trials 1 to 4 and subsequently increased latency to
fall compared to untrained Cyfip1HET mice, suggesting that
sustained motor training during the development is suffi-
cient to alleviate the motor deficits of adult Cyfip1HET mice
(Fig. 4d).
Discussion
Three important conclusions can be drawn from this
study. First, we found that CYFIP1 binds to Neuroligin-3
Fig. 4 Motor training at early stages of development alleviates Cyfip1HET motor deficits. a, bWild-type and Cyfip1HET male mice improved their
latency to fall off the accelerating rod at P40. c Trained Cyfip1WT mice showed increased motor performances during the first two trials during the
behavioral assessment at P60 compared to untrained adult wild-type mice. d Trained Cyfip1HET mice increased their motor performances during the
rotarod testing compared to untrained Cyfip1HET mice. All values presented as mean ± SEM. Statistical significance was tested by repeated measures
ANOVA followed by Bonferroni post-hoc test. *P < 0.05; **P < 0.01; and ***P < 0.001
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at synapses and, directly or indirectly, to other proteins
associated with ASD. Second, we showed that Cyfip1HET
is associated with alterations of dendritic spine stability,
but not formation, and defects in social behavior and
motor learning. Finally, based on these findings we
designed a behavioral approach that alleviated the motor
learning phenotype of Cyfip1HET mice.
Dendritic spine defects as a converging phenotype in ASD
Previous work with genetic mouse models suggested
that the different genetic mutations associated with ASD
target a small set of molecular pathways, leading to a
deficit in dendritic spine morphogenesis10,11. Our study is
the first to provide direct evidence to support this
hypothesis. Importantly, defects in dendritic spine mor-
phology are also reported in human post-mortem studies,
showing that this pathophysiological feature is one of the
few conserved between mouse models and humans.
When studied in isolation, the impact of specific
monogenic genetic risk factors for ASD is limited by the
frequency of the mutations in the human population,
which is, in general, very low36. Our results demonstrate
that some of these risk factors are in fact directly con-
nected, such that they are likely to form a single molecular
pathway in which dysfunction can cause specific forms of
ASD. The frequency of such molecular alterations is likely
to be equivalent to the sum of the frequency of the genetic
risks, thus accounting for a large number of individuals
with ASD. It remains possible that independent pathways
regulating dendritic spine formation and function may
alter the composition of this cluster of ASD proteins,
suggesting that, not all cases of ASD associated where
such changes are present, can be attributed to a single
cause. Nevertheless, this finding is likely to provide a
framework to address the genetic heterogeneity associated
with ASD.
As such, analysis of dendritic spine morphology or
density cannot be conveniently used as a biomarker in the
human population, as it requires access to brain tissue. In
this context, our findings are more likely to represent a
step towards a better definition of some of the biological
basis of ASD, which in turn may lead to the identification
of biological markers. Indeed, dendritic spines are the
postsynaptic docking compartment for a large number of
excitatory synapses and decrease in their number and
stability is likely to have a direct consequence on the
number of synaptic inputs a neuron receives and, by
extension, a brain region receives. Such connectivity
between brain regions can be quantified in mice and
humans using diffusion tensor imaging. Using Cyfip1Het
mouse model, and by extension, any genetic model
associated with the ASD protein cluster could, therefore,
help to better understand the complex relationship
between brain region-specific defects in dendritic spine
stability and brain-wide connectivity providing an
experimental framework to identify biological markers for
specific behavioral phenotypes.
Predicted functional consequences associated with the
ASD cluster of proteins
Aberrant signaling through type 1 metabotropic gluta-
mate receptors 1 and 5 (mGluR1 and 5), resulting in
defects in long-term synaptic depression (LTD), is a
pathophysiological hallmark of genetic mouse models of
ASD37. Interestingly, mutations in genes associated with
the proteins co-immunoprecipitated with Neuroligin-3,
including Neuroligin-3 itself32,38 (but see ref. 39), CYFIP18,
FMRP40, MeCP241, Synaptic Ras GTPase-activating pro-
tein 1 (encoded by the Syngap1 gene)42, and the beta
3 subunit of Type A gamma-aminobutyric acid receptors
(encoded by the Gabrb3 gene)43, lead to such phenotypes.
These results indicate that in addition to regulating den-
dritic spine morphogenesis, this cluster of proteins might
be involved in regulation of mGluR1/5 function and
control of LTD.
At synapses, mGluR1/5 binds directly to Homer pro-
teins, which links the receptors to the endoplasmic reti-
culum (ER), via interactions with PI 3-kinase enhancer
(PIKE) and inositol 1,4,5-trisphosphate receptors (IP3Rs),
or to ionotropic glutamate receptors, via SH3 and mul-
tiple ankyrin repeat domains (Shank) proteins44. Our data
show that type 1 mGluR, and mGluR1 specifically, are
reliably co-immunoprecipitated with Neuroligin-3 in
cerebellar but not striatal Pvalb-expressing cells (Sup-
plementary Table 3). Moreover, along with mGluR1 we
also reliably detected PIKE (encoded by the Agap3 gene)
and IP3R1 (encoded by the Itpr1 gene) but not Shank
proteins or ionotropic receptors (Supplementary Table 3).
Interestingly, FMPR has been shown to inhibit PIKE and
therefore type 1 mGluR downstream signaling45. These
results raise the question of a potential involvement of
CYFIP1 in regulating type 1 mGluR downstream signal-
ing. It is possible that Neuroligin-3, FMRP, and CYFIP1
are expressed in different subcellular compartments of the
neurons and, therefore, do not aggregate in a single
cluster. Nevertheless, these results suggest that Neuroli-
gin-3, FMRP, and CYFIP1 are involved in localizing
mGluR1 and the ER at the synapse. The release of calcium
from the ER to the cytoplasm is regulated by mGluR1 and
essential for the induction of LTD46. Based on our results,
we can further speculate that defects in mGluR-LTD
observed in genetic mouse models for ASD result from an
inappropriate localization of the mGlur/ER complex at
the synapse, a hypothesis that remains to be experimen-
tally tested. Importantly, this mechanism might be cell
or type 1 mGluR specific as we did not reliably detect
type 1 mGluR in proteins co-immunoprecipitated with
Neuroligin-3 in the striatum.
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Behavioral treatment to alleviate ASD core and comorbid
symptoms
About 42% of individuals carrying 15q11.2 deletions
show motor delay2. Motor abnormalities and delay in
motor development are common comorbid symptoms in
more than 70% of individuals with ASD1. In this study, we
found that adult Cyfip1HET mice show defects in motor
learning. Note that we have not fully characterized the
motor learning deficits and it is possible that a less chal-
lenging paradigm, with longer interatrial intervals for
example, would find milder or no phenotype in Cyfip1HET
mice. Nevertheless, along with Cyfip1HET mice, other
mouse models for ASD show motor phenotypes47, sug-
gesting that, to a certain extent, mouse models of ASD
replicate motor abnormalities found in humans. Impor-
tantly, we found that training Cyfip1HET mice early in the
development is sufficient to alleviate the motor learning
phenotype in adult mice. These results demonstrate that
the motor learning phenotype of Cyfip1HET mice develops
over time, appearing between young adult and adult
stages, and is reversible using behavioral training
approaches. As future studies, it would be interesting to
know if dendritic spine phenotypes follow the similar
developmental trajectories and sensitivity to behavioral
training. These results provide important insights for the
treatment of motor impairment in ASD in humans. In
humans, motor impairments can be detected early in the
development alongside the diagnosis of ASD. Our results
suggest that early behavioral intervention, targeted at
stimulating motor function, might help in preventing
motor impairment arising later in life.
Materials and methods
Animals
All procedures were conducted in accordance with the
Animals (Scientific Procedures) Act 1986 (amended
2012). Nlgn3KO mice48 were crossed with OmpCre mice
(JAX: #00666849), where part of the Omp gene was
replaced by Cre recombinase. Nlgn3KO mice were also
crossed with PvalbCre mice, expressing Cre recombinase
under the Pvalb promoter (JAX:01732050). The Cyfip1tm2a
(EUCOMM)Wtsi (EUCOMM) mouse line was either bred
with BL6 mice to obtain Cyfip1Het and Cyfip1WT mice or
crossed with Tg(Thy1-EGFP)MJrs/J (JAX: # 00778851) to
obtain Thy1-EGFP-Cyfip1Het and Thy1-EGFP-Cyfip1WT
mice. Mice were kept on a 12 h light/dark cycle with free
access to food and water. All behaviors were assessed
during the light cycle and after mice were habituated for
30min to the testing room.
Biochemistry
Brain tissue from adult mice was sliced in 1.5–2mm
sections and micro-dissected prior to snap freezing and
storage at −80 °C. 10 µl of lysis buffer (1% SDS, 10 mM
hepes, protease inhibitors, phosphatase inhibitors, 1 mM
NaF, 1 mM NaVO4) was used per 1 mg of tissue. Using
Laemmli buffer samples were run on SDS–PAGE gels
(NuPAGE Novex 4–12% Bis–Tris, Protein gels, Invitro-
gen) and transferred on nitrocellulose membrane.
Immunoblotting was performed with antibodies raised
against CYFIP1 (anti-CYFIP1 ab156016, Abcam), β-III
Tubulin (801201, BioLegend), and GAPDH (83956,
Abcam). Blots were developed using ECL (Santa Cruz and
Advansta). Blots were digitally acquired by ChemiDoc
(Biorad) and quantified using Image Lab Software
(Biorad).
For synaptosome fractionation, mice were culled by
cervical dislocation, and the brains were immediately
dissected and homogenized in SynPer (Sigma-Aldrich)
containing protease cocktail inhibitors (Sigma-Aldrich)
and phosphatase inhibitors (10 mM NaF, 1 mM NaVO4).
Homogenized tissues were then centrifuged to give pel-
lets, resuspended in SynPer to obtain nuclear fractions,
and supernatants (i.e. homogenates). Part of the super-
natants was further centrifuged to give pellets, further
resuspended in SynPer® to give synaptosome fractions and
cytosolic fractions in supernatants. The samples were
then immediately processed for western blot analysis, or
immediately used for immunoprecipitation experiments.
For immunoprecipitation, tissues were dissected and
then homogenized in 100 ml of lysis buffer for each 10mg
of tissue (20mM Tris–HCl, 150mM NaCl, 1 mM EDTA,
1% Triton-X100, 10 mM NaF, 1 mM Na3VO4, protease
inhibitor cocktail (Sigma-Aldrich)). The samples were
centrifuged at 14,000 × g for 10 min at 4 °C and the
supernatant containing the proteins was removed. The
ethanol was removed from Sepharose beads coated with
Protein A (GE Healthcare Life Sciences) by two washes
with ice-cold phosphate-buffered saline, at 2000 × g for
2 min. The supernatant was pre-cleared by incubating
with Protein A-Sepharose beads for 30min at 4 °C. Pro-
tein A-Sepharose beads for immunoprecipitation were
washed with lysis buffer at 2000 × g for 2 min. Proteins
were then incubated for 2 h at 4 °C with Protein A-
Sepharose beads and Neuroligin-3 antibody (#129311,
Synaptic Systems, 1:1000). Unbound proteins were
removed by three washes with lysis buffer. Peptides were
then eluted in lithium dodecyl sulfate buffer (106 mM
Tris–HCl, 141 mM Tris-base, 2% LDS, 10% glycerol,
0.51 mM EDTA, 0.22 mM Brilliant Blue, 0.175 mM Phe-
nol Red, 10 mM DTT) at 70 °C for 10 min. Samples were
frozen at −20 °C for storage.
Mass-spectrometry analysis
Mass-spectrometry analysis was performed by the
University of Bristol Proteomics Facility. Each sample was
separated as a lane on an SDS–PAGE gel and electro-
phoresis was performed until the samples had run ~3 cm
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into the separating gel. The gel lane was then cut into
three slices and each slice subjected to in-gel tryptic
digestion using a DigestPro automated digestion unit
(Intavis Ltd.). The resulting peptides were fractionated
using an Ultimate 3000 nano-LC system in line with an
LTQ-Orbitrap Velos mass spectrometer (Thermo Scien-
tific). In brief, peptides in 1% (vol/vol) formic acid was
injected onto an Acclaim PepMap C18 nano-trap column
(Thermo Scientific). After washing with 0.5% (vol/vol)
acetonitrile 0.1% (vol/vol) formic acid peptides were
resolved on a 250mm× 75 μm Acclaim PepMap C18
reverse phase analytical column (Thermo Scientific) over
a 150 min organic gradient, using seven gradient segments
(1–6% solvent B over 1 min, 6–15% solvent B over 58min,
15–32% solvent B over 58min, 32–40% solvent B over
5 min, 40–90% solvent B over 1 min, held at 90% solvent B
for 6 min and then reduced to 1% solvent B over 1 min)
with a flow rate of 300ml min−1. Solvent A was 0.1%
formic acid and Solvent B was aqueous 80% acetonitrile in
0.1% formic acid. Peptides were ionized by nano-
electrospray ionization at 2.1 kV using a stainless-steel
emitter with an internal diameter of 30 μm (Thermo
Scientific) and a capillary temperature of 250 °C. Tandem
mass spectra were acquired using an LTQ- Orbitrap Velos
mass spectrometer controlled by Xcalibur 2.1 software
(Thermo Scientific) and operated in data-dependent
acquisition mode. The Orbitrap was set to analyze the
survey scans at 60,000 resolution (at m/z 400) in the mass
range m/z 300–2000 and the top 20 multiply charged ions
in each duty cycle selected for MS/MS in the LTQ linear
ion trap. Charge state filtering, where unassigned pre-
cursor ions were not selected for fragmentation, and
dynamic exclusion (repeat count, 1; repeat duration, 30 s;
exclusion list size, 500) were used. Fragmentation condi-
tions in the LTQ were as follows: normalized collision
energy, 40%; activation q, 0.25; activation time 10ms; and
minimum ion selection intensity, 500 counts.
The raw data files were processed and quantified using
Proteome Discoverer software v1.4 (Thermo Scientific)
and searched against the UniProt Mouse database
(78740 sequences) using the SEQUEST algorithm. Peptide
precursor mass tolerance was set at 10 ppm, and MS/MS
tolerance was set at 0.8 Da. Search criteria included car-
bamidomethylation of cysteine (+57.0214) as a fixed
modification and oxidation of methionine (+15.9949) as a
variable modification. Searches were performed with full
tryptic digestion and a maximum of one missed cleavage
was allowed. The reverse database search option was
enabled and all peptide data was filtered to satisfy false
discovery rate (FDR) of 5%.
Social interest
Social odors originated from two cages of three C57Bl/6
male mice with the different parental origins, maintained
for 6 days with the same home cage bedding to allow for a
concentration of odorants. Before the test, swabs were
wiped in a zig-zag pattern across the bottom surface of the
cage to collect the olfactory cues. Mice were acclimatized
for 30min to the presence of a cotton swab prior to
testing. Mice were then exposed to a cotton swab without
odor followed by a cotton swab with a social odor. During
the 2 min exploration periods, the time spent sniffing the
swab on the first exposure to each odor was recorded
manually and blind to the genotype.
Vocalization
We recorded ultrasonic vocalization (USV) emitted by
the male mice exposed to a female mouse in estrus (1, 2).
All male mice were first habituated for 3 min to the arena.
Following the habituation, an unfamiliar female mouse in
estrus was added to the same arena for 3 min. During this
time the mice could interact with each other freely in the
arena. The male vocalization behavior was recorded by a
preamplifier (UltraSoundGate 416 H, Avisoft Bioacous-
tics) connected microphone (UltraSoundGate CM16,
Avisoft Bioacoustics) placed above the arena. As pre-
viously described frequencies were recorded and analyzed
for the total number of emitted calls and the total time
spent calling using SASLabPro (Avisoft Bioacoustics).
Marble burying
Mice were in individual cages (28 cm × 17 cm) each
containing 20 marbles arranged in five rows of four
marbles on top of 4 cm deep bedding over the time course
of 30 min. The testing room used was dimly lit, with equal
light distribution for all mice in the trial. A marble was
buried when ≤50% of the marble was not visible. For
counting and quantification, experimenters were blind to
the genotype.
Rotarod behavior
Prior to the experiment mice were handled over the
course of 2 days. During a trial, the rod accelerated to
40 rpm within 5min. The latency to fall was evaluated
across seven subsequent trials with a rest period of 5 min
in between. The latency to fall was determined based on
the time spent on the rod until the test mouse fell off,
gripped to the rod and followed the rod for a full rotation
or the testing trial ended after 5 min.
Activity and anxiety behavior
Spontaneous activity of the mice was tested in an open
field arena (40 cm × 40 cm) for 20min, in the dark. The
mice were able to freely move and explore the environ-
ment during the test. The behavior was recorded by a
computer linked video camera located above the arena.
The arena was illuminated from the bottom by an infrared
light source, for detection of the mice. EthoVision XT
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(Noldus) software was used for tracking and quantifica-
tion of the average velocity.
Immunohistology
Thy-1 GFP-expressing Cyfip1WT and Cyfip1HET mice
were anesthetized and perfused with 4% paraformalde-
hyde in 0.1M phosphate buffer (PB). Brains were post-
fixed overnight, stored in OCT at −80 °C, then cut cor-
onally into 50 μm sections on a cryostat (Leica Biosys-
tems, Germany) and mounted on a series of glass slides.
Confocal images were acquired on a Zeiss LSM700
upright confocal microscope (Carl Zeiss, Welwyn Garden
City, UK), using a ×43 water immersion lens (NA= 1.3).
At least 10 Z-stack images (2048 × 2048 pixels) spaced
0.5 μm apart were acquired in the primary motor and
visual cortices of each animal, focusing on secondary
branching dendrites from cells. Series stacks were
reconstructed into two dimensions according to Z-stack
projections of maximum intensity in ImageJ (NIH, USA,
public domain). All images were coded at the time of
acquisition and analyzed blinded to the experimental
condition. Spines were manually identified and counted
on 60–150 μm long dendrites, with N= 24 dendrites
(from four mice) per condition analyzed. Spine density
was calculated as the number of spines per 10 μm of
dendrites.
Structural plasticity imaging in vivo
Dendritic spine imaging was performed in awake and
head fixed Thy-1 GFP-expressing Cyfip1WT and Cyfi-
p1HET adult male mice (from postnatal day 60) with
implanted cranial windows. Aseptic surgical procedures
were conducted based on previously described proto-
cols35. Approximately one hour prior to cranial window
surgery, animals were administered with the antibiotic
Baytril (5 mg/kg, s.c.) and the anti-inflammatory drugs
carprofen (5 mg/kg, s.c.) and dexamethasone (0.15 mg/kg,
i.m.). Anesthesia was induced then maintained using
isoflurane at concentrations of 4%, then 1.5–2%, respec-
tively. After animals were secured in a stereotaxic frame,
the scalp and periosteum were removed from the dorsal
surface of the skull, and a custom head plate was attached
to the cranium using dental cement (Super Bond C&B),
with an aperture approximately centered over right M1. A
3mm circular craniotomy was next performed, centered
over the forelimb area using stereotaxic coordinates
1.3 mm anterior to the bregma and 1.2 mm lateral from
the midline. The craniotomy was then closed with a glass
insert constructed from three layers of circular no. 1
thickness glass (1 × 5 mm, 2 × 3mm diameter) bonded
together with an optical adhesive (Norland Products;
catalog no. 7106). Mice were imaged one-week post-sur-
gery. Initial dendritic spine imaging was followed up after
2, 7, and 9 days. In vivo 2-photon imaging was performed
using a resonant scanning microscope (Thorlabs, B-
Scope) with a ×16 0.8NA objective with 3 mm working
distance (Nikon). eGFP was excited at 980 nm using a Ti:
sapphire laser (Coherent, Chameleon) with a maximum
laser power at the sample of 20 mW. Z stacks were
acquired at a frame rate of ~30 Hz, with 20 frames per
depth, from 15 depths spaced by 2 µm. Imaged stretches
of dendrite close to parallel to the imaging plane were
selected based on an eGFP expression which was traced
back to the soma located in layer 5 (Z: 400–500 µm from
brain surface). Cortical surface vascular landmarks were
used to locate the same stretches of dendrite between
sessions. During two-photon imaging animals were free to
run on a custom designed fixed axis cylindrical treadmill,
and data collection was limited to stationary periods to
avoid locomotion related brain movement. Imaging data
were acquired using Scanimage 4.1 (HHMI Janelia).
Imaging data were first corrected for brain motion using
an automated rigid registration algorithm implemented in
Matlab (MathWorks). The 20 frames from each depth
were then averaged and a maximum intensity projection
calculated over the z planes which encompassed the
stretch of the dendrite of interest. Formed and eliminated
spines were manually counted and normalized to 100 µm
of dendrite (Thy1-EGFP-Cyfip1Het N= 36, from four
mice; Thy1-EGFP-Cyfip1WT N= 40, from four mice).
Statistical analysis
Prior the cluster analysis, every protein detected in
immunoprecipitates from VNO of Nlgn3KO mice (Sup-
plementary Table 2) was filtered out of the ones immu-
noprecipitated from wild-type mice VNO (Supplementary
Table 2) and Nlgn3KOPvalbCre striatum and cerebellum
(Supplementary Table 1), because proteins present in
Nlgn3KO are likely to be false positives. The list of
remaining proteins can be found in Supplementary Table
3. A protein was considered detected when its score was
>0, therefore obtaining a binarized dataset containing
proteins detected (score of 1) and non-detected (score of
0) for each technical triplicate and each anatomical
region. We used SPSS Statistics® software to perform
hierarchical cluster analysis based on the binarized score
and determined that three clusters described the dataset
best. We then performed a two-step analysis with three
clusters and obtained the results presented in Fig. 1.
Supplementary Table 4 contains the data structure, type
of test used, observed power and N for Figs. 3 and 4. Each
test included enough animals to reach a power close to or
above 0.8. We designed our tests groups to have mice
from the different groups tested at the same time. We
used SPSS Statistics® software to systematically test for
normality using Levene’s test. No animals were removed
from the analyses. Pairwise comparisons were analyzed by
two-tailed Student’s t-test for normally distributed
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datasets or two-tailed Mann–Whitney’s test for non-
normally distributed datasets. All datasets used for two-
way non-repeated and repeated measure ANOVAs were
normally distributed and, when appropriate, followed by
post-hoc Bonferroni’s test.
Acknowledgements
We thank Y. Barde for insightful comments on the manuscript. We thank Kate
Heesom and her team at the University of Bristol Proteomics Facility for the
support with the mass-spectrometry analysis. This work was supported by the
Life Science Research Network Wales, an initiative funded through the Welsh
Government’s Ser Cymru program, by a Wellcome Trust Strategic Award
(503147) and by a Wellcome Trust Seed Award (201991) to S.J.B. and Wellcome
Trust studentships to M.S., E.C. and S.W.
Author details
1School of Biosciences, Cardiff University, Cardiff CF10 3AX Wales, UK.
2Neuroscience and Mental Health Research Institute, School of Medicine,
Cardiff University, Cardiff CF24 4HQ, UK. 3Faculty of Medicine and Health
Sciences, Universitat Internacional de Catalunya, Barcelona, Spain
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Supplementary information accompanies this paper at (https://doi.org/
10.1038/s41398-018-0338-9).
Received: 27 July 2018 Revised: 15 November 2018 Accepted: 25
November 2018
Published online: 21 January 2019
References
1. Lai, M. C., Lombardo, M. V. & Baron-Cohen, S. Autism. Lancet 383, 896–910
(2014).
2. Cox, D. M. & Butler, M. G. The 15q11.2 BP1-BP2 microdeletion syndrome: a
review. Int. J. Mol. Sci. 16, 4068–4082 (2015).
3. Butler, M. G., Bittel, D. C., Kibiryeva, N., Talebizadeh, Z. & Thompson, T. Beha-
vioral differences among subjects with Prader-Willi syndrome and type I or
type II deletion and maternal disomy. Pediatrics 113, 565–573 (2004).
4. Bittel, D. C., Kibiryeva, N. & Butler, M. G. Expression of 4 genes between
chromosome 15 breakpoints 1 and 2 and behavioral outcomes in Prader-Willi
syndrome. Pediatrics 118, e1276–e1283 (2006).
5. Chen, B. et al. The WAVE regulatory complex links diverse receptors to the
actin cytoskeleton. Cell 156, 195–207 (2014).
6. Chen, Z. et al. Structure and control of the actin regulatory WAVE complex.
Nature 468, 533–538 (2010).
7. De Rubeis, S. et al. CYFIP1 coordinates mRNA translation and cytoskeleton
remodeling to ensure proper dendritic spine formation. Neuron 79,
1169–1182 (2013).
8. Bozdagi, O. et al. Haploinsufficiency of Cyfip1 produces fragile X-like pheno-
types in mice. PLoS One 7, e42422 (2012).
9. Pathania, M. et al. The autism and schizophrenia associated gene CYFIP1 is
critical for the maintenance of dendritic complexity and the stabilization of
mature spines. Transl. Psychiatry 4, e374 (2014).
10. Forrest, M. P., Parnell, E. & Penzes, P. Dendritic structural plasticity and neu-
ropsychiatric disease. Nat. Rev. Neurosci. 19, 215–234 (2018).
11. Phillips, M. & Pozzo-Miller, L. Dendritic spine dysgenesis in autism related
disorders. Neurosci. Lett. 601, 30–40 (2015).
12. Auerbach, B. D., OsterweilE. K. & Bear, M. F. Mutations causing syndromic
autism define an axis of synaptic pathophysiology. Nature 480, 63–68
(2011).
13. Chung, L. et al. Parental origin impairment of synaptic functions and behaviors
in cytoplasmic FMRP interacting protein 1 (Cyfip1) deficient mice. Brain Res.
1629, 340–350 (2015).
14. Jamain, S. et al. Mutations of the X-linked genes encoding neuroligins NLGN3
and NLGN4 are associated with autism. Nat. Genet. 34, 27–29 (2003).
15. Glessner, J. T. et al. Autism genome-wide copy number variation reveals
ubiquitin and neuronal genes. Nature 459, 569–573 (2009).
16. Ylisaukko-oja, T. et al. Analysis of four neuroligin genes as candidates for
autism. Eur. J. Hum. Genet. 13, 1285–1292 (2005).
17. Sanders, S. J. et al. Multiple recurrent de novo CNVs, including duplications of
the 7q11.23 Williams syndrome region, are strongly associated with autism.
Neuron 70, 863–885 (2011).
18. Levy, D. et al. Rare de novo and transmitted copy-number variation in autistic
spectrum disorders. Neuron 70, 886–897 (2011).
19. CY, R. K. et al. Whole genome sequencing resource identifies 18 new candi-
date genes for autism spectrum disorder. Nat. Neurosci. 20, 602–611 (2017).
20. Radyushkin, K. et al. Neuroligin-3-deficient mice: model of a monogenic
heritable form of autism with an olfactory deficit. Genes Brain Behav. 8,
416–425 (2009).
21. Kalbassi, S., Bachmann, S. O., Cross, E., Roberton, V. H., Baudouin, S. J. Male and
female mice lacking neuroligin-3 modify the behavior of their wild-type lit-
termates. eNeuro 4, eneuro. 0145–17 (2017).
22. Tabuchi, K. et al. Neuroligin-3 mutation implicated in autism increases inhi-
bitory synaptic transmission in mice. Science 318, 71–76 (2007).
23. Jaramillo, T. C., Liu, S., Pettersen, A., Birnbaum, S. G. & Powell, C. M. Autism-
related neuroligin-3 mutation alters social behavior and spatial learning. Aut-
ism Res. 7, 264–272 (2014).
24. Chadman, K. K. et al. Minimal aberrant behavioral phenotypes of neuroligin-3
R451C knockin mice. Autism Res. 1, 147–158 (2008).
25. Michalon, A. et al. Chronic pharmacological mGlu5 inhibition corrects fragile X
in adult mice. Neuron 74, 49–56 (2012).
26. Isshiki, M. et al. Enhanced synapse remodelling as a common phenotype in
mouse models of autism. Nat. Commun. 5, 4742 (2014).
27. Wijetunge, L. S., Angibaud, J., Frick, A., Kind, P. C. & Nagerl, U. V. Stimulated
emission depletion (STED) microscopy reveals nanoscale defects in the
developmental trajectory of dendritic spine morphogenesis in a mouse
model of fragile X syndrome. J. Neurosci. 34, 6405–6412 (2014).
28. Sudhof, T. C. Neuroligins and neurexins link synaptic function to cognitive
disease. Nature 455, 903–911 (2008).
29. Stogsdill, J. A. et al. Astrocytic neuroligins control astrocyte morphogenesis
and synaptogenesis. Nature 551, 192–197 (2017).
30. Gilbert, M., Smith, J., Roskams, A. J. & Auld, V. J. Neuroligin 3 is a vertebrate
gliotactin expressed in the olfactory ensheathing glia, a growth-promoting
class of macroglia. Glia 34, 151–164 (2001).
31. Rothwell, P. E. et al. Autism-associated neuroligin-3 mutations commonly
impair striatal circuits to boost repetitive behaviors. Cell 158, 198–212 (2014).
32. Baudouin, S. J. et al. Shared synaptic pathophysiology in syndromic and
nonsyndromic rodent models of autism. Science (N. Y., NY) 338, 128–132
(2012).
33. Koekkoek, S. K. E. et al. Deletion of FMR1 in Purkinje cells enhances parallel
fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in
fragile X syndrome. Neuron 47, 339–352 (2005).
34. Roy, S. et al. Comprehensive motor testing in Fmr1-KO mice exposes temporal
defects in oromotor coordination. Behav. Neurosci. 125, 962–969 (2011).
35. Yang, G., Pan, F. & Gan, W. B. Stably maintained dendritic spines are associated
with lifelong memories. Nature 462, 920–924 (2009).
36. Spooren, W., Lindemann, L., Ghosh, A. & Santarelli, L. Synapse dysfunction in
autism: a molecular medicine approach to drug discovery in neurodevelop-
mental disorders. Trends Pharmacol. Sci. 33, 669–684 (2012).
37. D’Antoni, S. et al. Dysregulation of group-I metabotropic glutamate (mGlu)
receptor mediated signalling in disorders associated with Intellectual Disability
and Autism. Neurosci. Biobehav. Rev. 46, 228–241 (2014).
38. Martella, G. et al. The neurobiological bases of autism spectrum disorders: the
R451C-neuroligin 3 mutation hampers the expression of long-term synaptic
depression in the dorsal striatum. Eur. J. Neurosci. 47, 701–708 (2017).
39. Zhang, B. et al. Neuroligins sculpt cerebellar Purkinje-cell circuits by differential
control of distinct classes of synapses. Neuron 87, 781–796 (2015).
40. Bear, M. F., Huber, K. M., Warren, S. T. The mGIuR theory of fragile X mental
retardation. Trends Neurosci. 27, 370–377 (2004).
Bachmann et al. Translational Psychiatry (2019)9:29 Page 11 of 12
41. Gogliotti, R. G. et al. mGlu5 positive allosteric modulation normalizes synaptic
plasticity defects and motor phenotypes in a mouse model of Rett syndrome.
Hum. Mol. Genet. 25, 1990–2004 (2016).
42. Barnes, S. A. et al. Convergence of hippocampal pathophysiology in syngap
+ /- and Fmr1-/y mice. J. Neurosci. 35, 15073–15081 (2015).
43. Mercer, A. A., Palarz, K. J., Tabatadze, N., Woolley, C. S., Raman, I. M.
Sex differences in cerebellar synaptic transmission and sex-specific
responses to autism-linked Gabrb3 mutations in mice. eLife 5, e07596
(2016).
44. Shiraishi-Yamaguchi, Y. & Furuichi, T. The Homer family proteins. Genome Biol.
8, 206 (2007).
45. Sharma, A. et al. Dysregulation of mTOR signaling in fragile X syndrome. J.
Neurosci. 30, 694–702 (2010).
46. Kano, M., Hashimoto, K. & Tabata, T. Type-1 metabotropic glutamate receptor
in cerebellar Purkinje cells: a key molecule responsible for long-term
depression, endocannabinoid signalling and synapse elimination. Philos. Trans.
R. Soc. B 363, 2173–2186 (2008).
47. Schroeder, J. C., Reim, D., Boeckers, T. M. & Schmeisser, M. J. Genetic animal
models for autism spectrum disorder. Curr. Top. Behav. Neurosci. 30, 311–324
(2017).
48. Tanaka, K. F. et al. Flexible accelerated STOP tetracycline operator-knockin
(FAST): a versatile and efficient new gene modulating system. Biol. Psychiatry
67, 770–773 (2010).
49. Li, J., Ishii, T., Feinstein, P. & Mombaerts, P. Odorant receptor gene choice is
reset by nuclear transfer from mouse olfactory sensory neurons. Nature 428,
393–399 (2004).
50. Hippenmeyer, S. et al. A developmental switch in the response of DRG
neurons to ETS transcription factor signaling. PLoS Biol. 3, e159 (2005).
51. Feng, G. et al. Imaging neuronal subsets in transgenic mice expressing mul-
tiple spectral variants of GFP. Neuron 28, 41–51 (2000).
Bachmann et al. Translational Psychiatry (2019)9:29 Page 12 of 12
